Section Arrow
Quote
REVB.NASDAQ
- Revelation Biosciences Inc
Quotes are at least 15-min delayed:2025/06/04 05:22 EDT
Last
 0.9007
+0.0777 (+9.44%)
Day High 
1.15 
Prev. Close
0.823 
1-M High
3.34 
Volume 
47.07M 
Bid
0.8252
Ask
0.8403
Day Low
0.8723 
Open
1.03 
1-M Low
0.7749 
Market Cap 
793.20K 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2 
20-SMA 2.53 
50-SMA 2.79 
52-W High 60.8 
52-W Low 0.7749 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-82.07/-8.09
Enterprise Value
793.20K
Balance Sheet
Book Value Per Share
2.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed：2025/06/04 05:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products basedon Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.